BOSTON, MA, February 14, 2019 – Invicro LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, today announced the hiring of Dr. Joseph Krueger as Vice President, Research and Applications for Advanced Pathology Services.
Dr. Krueger brings more than 15 years of in vivo and ex vivo experience in evaluating disease, PK/PD, efficacy and biomarker hypotheses for drug development. Dr. Krueger will drive Invicro’s tissue biomarker application strategy and development activity to support pharmaceutical and biotech sponsors.
“Joe brings a wealth of knowledge and experience in cancer biology and computational pathology to the organization,” said Dr. Kenneth Bloom, Chief Medical Officer, Advanced Pathology & Genomics Services for Invicro. “We are very excited that he has joined our leadership team, working to help our clients improve precision medicine.”
Prior to joining Invicro, Dr. Krueger was Chief Science Officer at Flagship Biosciences Inc., where he led the R&D and Scientific efforts in applying novel quantitative tissue image analysis approaches to immuno-oncology and rare diseases to support drug and companion diagnostic development. Prior to Flagship Biosciences, he served in senior scientific roles in oncology drug development for OSI Pharmaceuticals in Boulder, CO and Pfizer in Andover, MA.
“I am looking forward to help expand the growth and innovation of Invicro’s Advanced Pathology Services business, by leveraging the synergies of Invicro’s market leading ex vivo imaging capabilities, such as Cryo-Fluorescence Tomography (CFT) and Konica-Minolta’s unique Phosphor Integrated Dot (PID) technology, “stated Dr. Krueger. “It will be exciting to help develop novel approaches with high resolution and sensitivity that allow the evaluation of drugs and biomarkers in tissue, which can accelerate drug development and bring groundbreaking precision medicine methods to patients.”
Dr. Krueger did his postdoctoral fellowship at The Scripps Research Institute and UC San Diego after completing his Ph.D. in Cancer Biology at Wayne State University in Detroit, MI.
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, cardiology, and pulmonary. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®.
As part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. For more information, visit www.invicro.com.
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/
VP, Global Marketing